Viatris Past Earnings Performance

Past criteria checks 1/6

Viatris has been growing earnings at an average annual rate of 32.8%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 9.3% per year. Viatris's return on equity is 0.3%, and it has net margins of 0.4%.

Key information

32.8%

Earnings growth rate

22.2%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	9.3%
Return on equity	0.3%
Net Margin	0.4%
Next Earnings Update	09 May 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Viatris makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:VTRS Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	15,427	55	3,753	802
30 Sep 23	15,466	1,832	3,682	817
30 Jun 23	15,602	1,854	3,653	781
31 Mar 23	15,800	1,904	3,553	735
31 Dec 22	16,263	2,079	3,518	661
30 Sep 22	16,728	804	3,584	745
30 Jun 22	17,187	761	3,678	719
31 Mar 22	17,648	168	4,101	711
31 Dec 21	17,886	-1,269	4,245	668
30 Sep 21	17,168	-1,921	4,802	625
30 Jun 21	15,604	-2,047	4,382	603
31 Mar 21	13,757	-1,728	3,686	565
31 Dec 20	11,946	-670	2,686	550
30 Sep 20	11,514	266	2,445	486
30 Jun 20	11,504	271	2,427	487
31 Mar 20	11,624	63	2,503	492
31 Dec 19	11,501	17	2,503	519
30 Sep 19	11,387	48	2,445	519
30 Jun 19	11,288	34	2,452	532
31 Mar 19	11,245	240	2,378	568
31 Dec 18	11,434	353	2,397	586
30 Sep 18	11,594	546	2,303	622
30 Jun 18	11,719	457	2,385	648
31 Mar 18	11,873	717	2,435	663
31 Dec 17	11,908	696	2,564	666
30 Sep 17	11,937	869	2,357	655
30 Jun 17	12,007	661	2,356	665
31 Mar 17	11,605	533	2,300	663
31 Dec 16	11,077	480	2,351	698
30 Sep 16	10,300	257	2,150	691
30 Jun 16	9,938	806	2,019	688
31 Mar 16	9,749	805	1,973	687
31 Dec 15	9,429	848	1,924	652
30 Sep 15	9,021	842	1,885	645
30 Jun 15	8,410	913	1,767	628
31 Mar 15	7,876	870	1,616	599
31 Dec 14	7,720	929	1,499	564
30 Sep 14	7,445	920	1,474	544
30 Jun 14	7,129	580	1,398	499
31 Mar 14	6,993	633	1,326	470
31 Dec 13	6,909	624	1,338	456
30 Sep 13	6,823	605	1,294	439
30 Jun 13	6,858	658	1,291	430

Quality Earnings: VTRS has a large one-off loss of $1.6B impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: VTRS's current net profit margins (0.4%) are lower than last year (12.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VTRS's earnings have grown significantly by 32.8% per year over the past 5 years.

Accelerating Growth: VTRS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VTRS had negative earnings growth (-97.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-6.8%).

Return on Equity

High ROE: VTRS's Return on Equity (0.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Viatris Past Earnings Performance

Past criteria checks 1/6

Key information

Recent past performance updates

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Price target decreased to US$12.55

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Viatris stock rises amid potential plans for €3B sale of European OTC assets

Take These Broken Wings And Learn To Fly Again Viatris

Viatris: 5% Dividend Yield Is A Threat For Investors

Independent Non-Executive Director recently sold US$100k worth of stock

Viatris: Products, Profitability And Pipeline - The Keys To Success

Upcoming dividend of US$0.12 per share

Consensus forecasts updated

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris declares $0.12 dividend

Viatris: A Spinoff To Own

Viatris extends decline to reach 52-week low

Revenue & Expenses Breakdown
Beta